MMP14 and central nervous system cancer: To determine whether MT1-MMP could be considered as an appropriate biomarker for gliomas, we studied its expression in a panel of 40 human glioma samples (WHO grade I, II and IV) by tissue microarray immunohistochemical analysis, using the anti-MT1-MMP LEM 2/15 antibody.